Quabodepistat (previously known as OPC-167832) is a medicine with a new mechanism of action that has potent antituberculosis activity and a favourable safety profile. Despite premature termination of PAN-TB Consortium trials including quabodepistat – since the trial does not support the investigational regimens being able to achieve the trial objective of identifying a new regimen to treat tuberculosis in 3 months or less – Otsuka plans to study the drug with bedaquiline and delamanid in phase III trials. The primary patent on quabodepistat has been granted in more than 50 LMICs and is expected to expire in 2035. There are secondary patents on intermediates and combinations that may provide exclusivity until 2037-2039 in many LMICs.

Patent & licence data in LMICs

Acronyms & abbreviations list